A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-272 in Healthy Subjects
Latest Information Update: 07 Apr 2026
At a glance
- Drugs VX 272 (Primary)
- Indications Cystic fibrosis
- Focus Adverse reactions
- Sponsors Vertex Pharmaceuticals
Most Recent Events
- 31 Mar 2026 Status changed from not yet recruiting to recruiting.
- 05 Mar 2026 New trial record